On 05/15/2013, Quick-Med Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Quick-Med Technologies Inc. announced that Viridis BioPharma Pvt. Ltd. has been granted an expanded license to sell Microfoam(TM) dressings. Microfoam is the first advanced wound care dressing to utilize Quick-Med's proprietary non-leaching NIMBUS(R) technology. Viridis will have the right to sell the Microfoam dressings it produces under license from Quick-Med to territories now including the Commonwealth of Independent States (CIS). Countries within the expanded territory include Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, as well as Georgia, Turkmenistan and the Ukraine. Distribution into these territories will be handled by Unique Pharmaceutical Labs, a company based in India, that has an extensive sales and commercial networks in the territories granted. The regulatory clearance process is already underway for Russia, with others following. This expanded contract has a term of 5 years. The core contract between Viridis and QMT that permits manufacture and sale in India of foam and gauze NIMBUS products is extended for the same period.

Quick-Med Technologies Inc. announced that the Board has appointed new members Dale Berman and Paul Jenssen effective February 28, 2013. These members fill vacancies left by departures of Major General George Friel, USA (Ret.), who served from 2000 to 2012, and J. Ladd Greeno, who served from 2007 to 2013. The board of directors expects to appoint Mr. Bergman to its audit committee. Mr. Jenssen has served as Chief Financial Officer and Corporate Secretary for Quick-Med Technologies since January 10, 2013. He has over 35 years of experience in strategic planning, process improvement, finance and accounting.